Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NUDT15 | Q9NV35 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GHSR | Q92847 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322343 | 0.88 | ALDH1A1 (0.53) | L3MBTL1ALDH1A1MAPTATMF10 | |
| SCHEMBL6152346 | 0.85 | ALDH1A1 (0.59) | L3MBTL1ALDH1A1MAPTATMF10 | |
| SCHEMBL6152664 | 0.85 | F10 (0.65) | L3MBTL1ALDH1A1MAPTATMF10 | |
| SCHEMBL5323222 | 0.85 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1MAPTATMF10 | |
| SCHEMBL5327115 | 0.84 | GHSR (0.50) | L3MBTL1NUDT15MAPTGHSRATM | |
| SCHEMBL5324846 | 0.84 | HRH3 (0.54) | L3MBTL1NUDT15MAPTGHSRATM | |
| SCHEMBL5327745 | 0.84 | MAPT (0.52) | L3MBTL1ALDH1A1MAPTF10THRB | |
| SCHEMBL5326485 | 0.84 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1MAPTATMF10 | |
| SCHEMBL5324555 | 0.82 | ATM (0.63) | L3MBTL1NUDT15GHSRATMF10 | |
| SCHEMBL14095701 | 0.78 | F10 (0.50) | L3MBTL1ALDH1A1MAPTATMF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007019397-A2 | 6-MEMBERED ARYL AND HETEROARYL DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS | GENELABS TECHNOLOGIES, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032488-A1 | 6-Membered aryl and heteroaryl derivatives for treating viruses | GENELABS TECHNOLOGIES, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008145-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032488-A1 | 6-Membered aryl and heteroaryl derivatives for treating viruses | HAVCR2, MAVS, EIF2AK2 | L3MBTL1 885/4885ALDH1A1 1740/4885NUDT15 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.